GlassScriptPhysician profile
Marie Prato
NPI 1679924815
$692.68
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $199 · 2021: $63.10 · 2022: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $330.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2019 | |
| Pfizer INC. | $58.38 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $43.08 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $33.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.90 | 2021-2022 | |
| Lilly USA, LLC | $20.91 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.28 | 2020 | |
| La Jolla Pharmaceutical Company | $14.61 | 2020 | |
| Merck Sharp & Dohme LLC | $13.18 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Prato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.